Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2842-2849

  Mark, Tomer M ^a   Bowman, Isaac A ^a   Rossi, Adriana C ^a   Shah, Manan ^a   Rodriguez, Melissa ^a   Quinn, Ryann ^a   Pearse, Roger N ^a   Zafar, Faiza ^a   Pekle, Karen ^a   Jayabalan, David ^a   Ely, Scott ^a   Coleman, Morton ^a   Chen Kiang, Selina ^a   Niesvizky, Ruben ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Clarithromycin; Dexamethasone; Lenalidomide; Newly diagnosed multiple myeloma; Thalidomide

Indexed keywords

CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; PLERIXAFOR; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ANOREXIA; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; BLOOD TOXICITY; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSGEUSIA; ENTEROCOCCAL INFECTION; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; KIDNEY FAILURE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; RESTLESSNESS; SEPTIC SHOCK; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEAKNESS; ANALOGS AND DERIVATIVES; AUTOTRANSPLANTATION; CLINICAL TRIAL; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLARITHROMYCIN; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84919421278     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.896005     Document Type: Article

References (31)

1. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122: 3456-3463.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
3. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma:A randomised phase 3 study. Lancet 2010;376:2075-2085.
4. Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012; 97: 442-450.
5. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-1769.
6. Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012;120:1589-1596.
7. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946-2955.
8. Sedlarikova L, Kubiczkova L, Sevcikova S, et al. Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res 2012; 36:1218-1224.
9. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-39.
10. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
11. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-4323.
12. Weber D, Rankin K, Gavino M, et al. T alidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-19.
13. Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse Effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004;117:508-515.
14. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-4053.
15. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma:An open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
16. Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2010;115:1343-1350.
17. Saloura V, Grivas PD. Lenalidomide: a synthetic compound with an evolving role in cancer management. Hematology 2010; 15: 318-331.
18. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete-and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111:1101-1109.
19. Rossi A, Mark T, Jayabalan D, et al. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood 2013;121:1982-1985.
20. Fost DA, Leung DY, Martin RJ, et al. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol 1999;103:1031-1035.
21. Gay F, Rajkumar SV, Coleman M, et al. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 2010;85:664-669.
22. Khan AA, Slifer TR, Araujo FG, et al. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 1999;11:121-132.
23. Stewart AK, Trudel S, Al-Berouti BM, et al. Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. Blood 1999;93:4441-4442.
24. Richardson PG, Schlossman RL, Weller E, et al. Immuno-modulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
25. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
26. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
27. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375-4382.
28. Jakubowiak AJ, Dytfeld D, Grifth KA, et al. A phase 1/2 study of carf lzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120:1801-1809.
29. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup:report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117:4701-4705.
30. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
31. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679-686.